SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-012457
Filing Date
2023-04-17
Accepted
2023-04-17 09:00:10
Documents
12
Period of Report
2023-04-17
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 34942
  Complete submission text file 0001493152-23-012457.txt   203114

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE pvct-20230417.xsd EX-101.SCH 3239
3 XBRL LABEL FILE pvct-20230417_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE pvct-20230417_pre.xml EX-101.PRE 22367
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3295
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

IRS No.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 23822985
SIC: 2834 Pharmaceutical Preparations